Method for human pluripotent stem cells

• US 20040111285A1
• Filed: 04/09/2003
• Published: 06/10/2004
• Est. Priority Date: 04/09/2002
• Status: Abandoned Application

• Current Assignee: Plurion, Inc. (Stem Cell Innovations, Inc.)
• Original Assignee: Plurion, Inc. (Stem Cell Innovations, Inc.)
• Inventors: Germain, Mark, Huizenga, David E., Perryman, David G.
• Application Number:
  US10/412,135
• Publication Number:
  US 20040111285A1
• Time in Patent Office: Days
• US Class Current: 705/1
• CPC Class Codes: G06Q 30/06 Buying, selling or leasing transactions
• CPC Class Codes: G06Q 40/00 Finance; Insurance; Tax strategies; Processing of corporate or income taxes

Abstract

This method provides a method relating to pluripotent stem cells, such as embryonic stem cells, to make the cells widely accessible but provide sufficient financial incentive to the provider of the cells. The method comprises obtaining the pluripotent stem cells and making the cells widely available to the public such that profit and non-profit institutions can afford research and commercial access to the cells.

Claims

1. A method of making pluripotent stem cells widely accessible for commercial use while providing sufficient financial incentive to the provider of the cells comprising obtaining the pluripotent stem cells and offering a commercial license to the cells with a royalty of 2% or less of net sales.

2. The method of claim 1, wherein the royalty is 1% or less.

3. The method of claim 1, wherein the royalty is ½

%, ¼

%, or ⅛

% or less.

4. The method of claim 1, further comprising a right to sub-license.

5. The method of claim 1, further comprising an upfront fee of less than $100,000.

6. The method of claim 1, further comprising an upfront fee of less than $1,000, $2,000, $3,000, $4,000, $10,000, $25,000, $50,000, or $75,000.

7. The method of claim 1, further comprising an upfront fee of about $0.

8. The method of claim 1, wherein the commercial license is to a for-profit company.

9. The method of claim 1, wherein the pluripotent cell is an ES cell.

10. The method of claim 1, further comprising computer software to implement the method.

11. The method of claim 1, wherein the commercial license is for all fields.

12. The method of claim 1, wherein the commercial license is for the fields of neural, cardiomyocyte or pancreatic islet cells derived from ES cells.